Fighting Chronic Inflammatory Diseases and Cancer with Precision!
OncoOne’s mission is to discover and deliver targeted medicines and solutions that address chronic inflammatory diseases and cancer to improve patient outcomes and quality of life effectively.
We Create Precision Medicines That Make a Real Difference for Patients
At OncoOne, our world-class team of antibody engineers specializes in developing and fine-tuning unique monoclonal antibodies, customized for complex and novel targets as well as specific therapeutic requirements. Our groundbreaking discovery of oxMIF, a disease-associated isoform of the macrophage migration inhibitory factor (MIF), ensures the precise delivery of our innovative medicines to effectively address chronic inflammatory diseases and cancer. By leveraging collaborations with leading experts and cutting-edge technologies like AI and in-depth data analysis, we strive to revolutionize standard-of-care treatments for underserved patient populations where substantial medical needs persist. Our aim is to deliver innovative treatments with unmatched safety and efficacy, surpassing mere symptom relief and making significant contributions to a healthier global community.
“Our vision runs deep, and our path is clear. We're fully committed to making a meaningful difference in people's lives through the innovative precision medicines we create together. It's our team's dedication to innovation and inclusivity, coupled with unwavering integrity, that drives every aspect of our work.”
- Randolf Kerschbaumer, CEO
Founders
Our founders, Randolf Kerschbaumer, Michael Thiele, and Alexander Schinagl, are the pioneers behind the novel therapeutic target oxMIF, playing a crucial role in shaping the future of medicine. As experts in antibody engineering, we endeavor to provide innovative treatments with the potential to alter the course of the disease, focusing on improving patients' quality of life rather than just managing symptoms.
Leadership
Leadership Team
Randolf Kerschbaumer, PhD
Co-Founder & Chief Executive Officer
Randolf Kerschbaumer, PhD
Co-Founder & Chief Executive Officer
Dr. Randolf Kerschbaumer, CEO and Co-Founder of OncoOne, brings over 25 years of experience from academia and big pharma R&D to the company. His comprehensive understanding of the drug development process, from early screening through to clinical trials, has been pivotal in shaping OncoOne's success. Under his leadership, OncoOne has expanded its reach globally and established a subsidiary in the USA. Randolf's intellectual curiosity, passion for science, and entrepreneurial drive allow him to effectively merge scientific innovation with strategic business planning. Before founding OncoOne, Randolf held several senior-level positions in R&D, focusing on therapeutics for cancer, inflammation, and hematologic disorders. He started his professional career at Baxter BioScience, progressing to senior leadership roles such as Head of Antibody Technology at Baxalta and Head of Oncology Research at Shire. His work has significantly contributed to the discovery and progression of antibody-based drug modalities with therapeutic potential from concept to Phase II clinical studies. Randolf earned his PhD in Biotechnology from the Vienna University of Natural Resources and Life Sciences (BOKU).
Michael Thiele, PhD
Co-Founder & Chief Scientific Officer
Michael Thiele, PhD
Co-Founder & Chief Scientific Officer
Michael, Co-Founder and Chief Scientific Officer (CSO) at OncoOne, has over two decades of expertise in immunology, tumor biology, biomarker discovery, and the development of biologics. As the CSO, he leads the company's strategic direction and drives the innovative PreTarg-it® platform, which aims for targeted delivery of therapies directly to tumor sites. Michael's profound knowledge of cell biology and his extensive global scientific connections enable him to establish and maintain strong partnerships with top experts in the field. Before establishing OncoOne, he led the Department of Cell Biology in Oncology Research at Shire. Earlier in his career, Michael held progressively senior roles at Baxter BioScience and its successor, Baxalta, collaborating with leading academics and industry leaders. Michael's significant contributions to medical science include recognizing oxMIF as a key therapeutic target, which marks a crucial advance in the creation of new therapies for autoimmune and chronic inflammatory conditions. Michael has been instrumental in advancing the first-generation anti-oxMIF antibody, imalumab, from early-stage research to phase II clinical trials. He obtained his PhD in Biology from the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen, where he investigated tumor-promoting and pro-inflammatory properties of MIF.
Alexander Schinagl, PhD
Co-Founder & Chief Technology Officer
Alexander Schinagl, PhD
Co-Founder & Chief Technology Officer
Alexander Schinagl, Co-Founder and Chief Technology Officer at OncoOne, plays a pivotal role in the company's antibody design and engineering programs. In addition, he provides IP counsel to ensure robust patent protection. Alexander demonstrated exceptional scientific leadership in over 15 years of experience in the biotechnology and pharmaceutical industries, where he has acquired a profound background in antibody engineering, drug discovery, development, and translational research. Before joining OncoOne, he was a Manager of R&D in Oncology Research at Shire where he led projects on antibodies and antibody-drug conjugates targeting oncological and hematologic disorders. Prior to that, he served in various positions with increasing levels of responsibility at Baxter BioScience and its successor, Baxalta, where Alexander significantly contributed to the development of the first generation of anti-oxMIF antibody, imalumab, supporting the progression from discovery through Phase II studies in various capacities. Alexander earned his PhD in biotechnology through an industry collaboration with Baxter BioScience and Baxalta from the University of Natural Resources and Life Sciences (BOKU) in Vienna.
Christine Landlinger-Schubert, PhD
Vice President Preclinical and Translational R&D
Christine Landlinger-Schubert, PhD
Vice President Preclinical and Translational R&D
Christine Landlinger-Schubert serves as Vice President of Preclinical and Translational R&D and leads the Inflammation program ON104 at OncoOne. She joined the company in 2021, bringing with her nearly 15 years of experience in drug discovery and non-clinical development in the biotech industry. At OncoOne, Christine has consistently showcased her exceptional leadership skills and has progressively taking on significant roles within the company. Before joining the company, Christine served as the Director of Lysins at PhagoMed, where she played a pivotal role in the development of pharmaceuticals to combat bacterial infections. In this role, she was instrumental in the European Union Institute of Innovation and Technology Health’s Goldtrack program, which ultimately led to the acquisition of PhagoMed by BioNTech. Prior to that, Christine served in various positions with increasing levels of responsibility at AFFiRiS, where she led preclinical activities for the development of active immunotherapies. Christine received her PhD in Life Science from the University of Vienna and conducted postdoctoral research at the Institute of Medical Biochemistry and the Children’s Cancer Research Institute in Vienna
Friedmund Bachmann
Vice President CMC
Friedmund Bachmann
Vice President CMC
Friedmund Bachmann serves as Vice President CMC and project lead for the Oncology program ON203 at OncoOne. With a rich experience spanning over two decades, Friedmund brings exceptional expertise in steering CMC programs across the entire product life cycle, showcasing his deep comprehension of the value chain for biological products. He became a part of the OncoOne team in 2021, consistently demonstrating outstanding leadership skills and leveraging his extensive knowledge to enhance our CMC department. Prior to his current role, he held various positions with ascending levels of responsibility within Pharmaceutical Sciences, CMC development, and CMC operations. His track record includes successful leadership of CMC programs encompassing the complete life cycle, spanning early-stage, late-stage, and commercial development for vaccines and products within oncology, hematology, and inflammatory diseases at prominent companies such as Baxter, Baxalta, Shire, and Takeda.
Maria Reitzinger, BA
Head of Finance and Administration
Maria Reitzinger, BA
Head of Finance and Administration
Maria Reitzinger serves as Head of Finance and Administration at OncoOne. Her extensive experience and background in cultural management bring a wealth of organizational and financial knowledge to our team. Since joining OncoOne in June 2020, Maria has continually expanded her responsibilities within the company, showcasing her adaptability and dedication. Prior to joining OncoOne, she served as the managing director of a prominent theater, where she was responsible for organizing festivals, concerts, and tourist events, demonstrating her expertise in responsible financial planning and effective project management. Maria holds a BA in Finance, Accounting, and Taxation from the University of Applied Sciences for Management & Communication.
Scientific Advisory Board
Prof. Michael Freissmuth, MD
Medical University Vienna, AT
Prof. Michael Freissmuth, MD
Director at Centre of Physiology & Pharmacology at Medical University Vienna
Dr. Freissmuth is the Director of the Center of Physiology & Pharmacology as well as the Chairman of the Institute of Pharmacology at the Medical University in Vienna. He was appointed Professor of Pharmacology in 1995 and received many awards, including the Novartis Award for Medicine. Dr. Freissmuth is a member of numerous editorial boards and serves on several review panels and scientific advisory boards. His most recent appointments include positions on international panels such as the Scientific Advisory Board of the Institut Cochin de Génétique Moléculaire in Paris and of the Engelhorn Foundation for Life Sciences. He is also a member of the supervisory board of Boehringer Ingelheim Austria. Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.
Prof. Dirk Jäger, MD
National Center for Tumor Diseases (NCT) Heidelberg, DE
Prof. Dirk Jäger, MD
Managing Director National Center for Tumor Diseases (NCT) Heidelberg
Dr. Jäger is Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg and Medical Director of the Medical Oncology Department at Heidelberg University Hospital, where he is responsible for the clinical research area representing all oncological departments. The main focus of his department is the translation of innovative treatment options into early clinical trials. Since 2005, Dr. Jäger has been head of the research laboratory for tumor immunology at the NCT and focuses on cancer immunotherapy. He also leads the Clinical Cooperation Unit of Applied Tumor Immunity and has received the Investigator Award from the Cancer Research Institute in New York.
Prof. em. Florian Rüker, PhD
University of Natural Resources and Life Sciences, AT
Prof. em. Florian Rüker, PhD
Former Head of the Department of Biotechnology at the University of Natural Resources and Life Sciences Vienna
Dr. Florian Rüker is an Associate Professor and was Deputy Head of the Department of Biotechnology and Head of the Institute of Molecular Biotechnology at the University of Natural Resources and Life Sciences, Vienna (BOKU), encompassing a team of more than 230. He is a co-founder of F-star and co-inventor of F-star’s core Modular Antibody Technology, which allows for the generation of antigen-binding sites in constant domains of immunoglobulins. Dr. Rüker serves F-star as a Scientific Advisor. He also founded the Christian Doppler Laboratory (CD-Lab) for Antibody Engineering at BOKU, where he acted as co-head. Subsequently, he supported the establishment of the CD-Lab for Innovative Immunotherapeutics in collaboration with F-star and Merck KGaA, where he acts as Scientific Advisor.
Prof. Seamas Donnelly, MD
Trinity College Dublin, IRE
Prof. Seamas Donnelly, MD
Professor & Head of Medicine at the Trinity College Dublin and Hon. Professor in Translational Medicine of the University of Edinburgh
Dr. Seamas Donnelly is a Professor of Medicine at Trinity College Dublin. He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies. He has authored many MIF-focused publications in renowned peer-reviewed journals, including Nature Medicine and Molecular Medicine. Dr. Donnelly’s research epitomizes classical bench to bedside on an international scale, and, in recognition of this, has been awarded an Honorary Professorship in Translational Medicine by the University of Edinburgh. He is the current President of the Association of Physicians of Great Britain & Ireland, the leading academic medical association in the UK and Ireland. Dr. Donnelly is also the lead Trinity PI of Health Innovation Hub Ireland and has been a member of OncoOne’s scientific advisory board since 2022.
Prof. Jennifer Guerriero, PhD
Harvard Medical School, US
Prof. Jennifer Guerriero, PhD
Assistant Professor, Harvard Medical School and Director of the Breast Tumor lmmunology Laboratory at the Dana Farber Cancer Institute.
Dr. Jennifer Guerriero is an Assistant Professor of Surgery at Harvard Medical School and Lead Investigator at Brigham and Women’s Hospital, Division of Breast Surgery, Department of Surgery. She also serves as the Director of the Breast Tumor Immunology Laboratory at the Dana-Farber Cancer Institute. Dr. Guerriero’s research interests include harnessing the anti-tumor potential of tumor-associated macrophages for cancer immunotherapy in breast cancer. Her group studies the role of tumor associated macrophages both in promoting tumorigenesis as well as how to harness macrophages for cancer therapy. The major goals of Dr. Guerriero’s work are to elucidate the molecular and functional regulation of tumor macrophage phenotype and subsets, identify how tumor macrophages inhibit T cell function and limit the effectiveness of immunotherapy and identify novel strategies to target macrophages therapeutically. Dr. Guerriero completed her postdoctoral training at Dana-Farber Cancer Institute where she investigated the role of tumor macrophages in breast cancer and identified novel mechanisms to target pro-tumor macrophages to an anti-tumor phenotype to induce tumor regression. Dr. Guerriero also serves on the board for the Society for Immunotherapy of Cancer.
Prof. Robert A. Mitchell, MD
University of Louisville, US
Prof. Robert A. Mitchell, MD
Professor in the Department of Surgery and a member of the Division of lmmunotherapy at the University of Louisville.
Dr. Robert Mitchell is a tenured Professor in the Department of Surgery and a member of the Division of Immunotherapy at the University of Louisville. He has joint/associate appointments in the Departments of Microbiology & Immunology and Biochemistry & Molecular Genetics. His research is concentrated on the study of immune tolerance in tumor biology. Specifically, his work focuses on the macrophage migration inhibitory factor (MIF) family of cytokines and their independent and coordinated influences on myeloid lineage-dependent T cell suppressive mechanisms which govern tumor-associated immune evasion and subsequent disease progression. He and his laboratory have developed numerous patented pharmaceutical agents that are designed to treat malignant and nonmalignant diseases and they are currently evaluating whether these compounds have a specific role in governing MIF-dependent mitochondrial homeostasis that dictates myeloid cell immune suppression.
Clinical Advisory Board
Prof. Michael Freissmuth, MD
Medical University Vienna, AT
Prof. Michael Freissmith, MD
Director at Centre of Physiology & Pharmacology at Medical University Vienna
Dr. Freissmuth is the Director of the Center of Physiology & Pharmacology as well as the Chairman of the Institute of Pharmacology at the Medical University in Vienna. He was appointed Professor of Pharmacology in 1995 and received many awards, including the Novartis Award for Medicine. Dr. Freissmuth is a member of numerous editorial boards and serves on several review panels and scientific advisory boards. His most recent appointments include positions on international panels such as the Scientific Advisory Board of the Institut Cochin de Génétique Moléculaire in Paris and of the Engelhorn Foundation for Life Sciences. He is also a member of the supervisory board of Boehringer Ingelheim Austria. Dr. Freissmuth is an inaugural member of OncoOne’s scientific advisory board, where he continues to support the development of the company’s pipeline of biotherapeutics.
Prof. Seamas Donnelly, MD
Trinity College Dublin, IRE
Prof. Seamas Donnelly, MD
Professor & Head of Medicine at the Trinity College Dublin and Hon. Professor in Translational Medicine of the University of Edinburgh
Dr. Seamas Donnelly is a Professor of Medicine at Trinity College Dublin. He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies. He has authored many MIF-focused publications in renowned peer-reviewed journals, including Nature Medicine and Molecular Medicine. Dr. Donnelly’s research epitomizes classical bench to bedside on an international scale, and, in recognition of this, has been awarded an Honorary Professorship in Translational Medicine by the University of Edinburgh. He is the current President of the Association of Physicians of Great Britain & Ireland, the leading academic medical association in the UK and Ireland. Dr. Donnelly is also the lead Trinity PI of Health Innovation Hub Ireland and has been a member of OncoOne’s scientific advisory board since 2022.
Prof. Richard Bucala, MD, PhD
Yale School of Medicine, US
Richard Bucala, MD, PhD
Chief of Rheumatology, Allergy & Immunology at the Yale Institute for Global Health and the Waldemar Von Zedtwitz Endowed Professor of Medicine, Pathology, Epidemiology, & Public Health at the Yale School of Medicine
Dr. Bucala is renowned in MIF research and is recognized for discovering MIF's receptor CD74 as well as elucidating MIF's critical role in regulating glucocorticoid immunosuppression. He is an attending physician in the Yale New Haven Health System and is the past Editor-in-Chief of Arthritis & Rheumatology. Dr. Bucala was elected to the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP), in addition to having served on an advisory board for the United Nations and various other U.S. federal, academic, and pharmaceutical organizations.
Prof. Daniel Aletaha, MD
Medical University Vienna, AT
Daniel Aletaha, MD
Professor and Head of the Clinical Department of Rheumatology at the Medical University of Vienna.
Dr. Aletaha was appointed as an Honorary Member of the European Alliance of Associations for Rheumatology (EULAR) in 2016, and in 2023, he was elected as its president. His research focuses on arthritis and other inflammatory rheumatic diseases, precision medicine, and the management of complex diseases. He has experience in the areas of novel therapies and treatment strategies, diagnosis, prognosis, outcomes, and biomarkers. He currently holds over 350 indexed publications.
Our team is highly committed to our shared goal of developing breakthrough cancer therapeutics.
Collaborating
We aim to partner with outstanding collaborators to propel pioneering treatments forward through flexible scientific approaches, swiftly bringing precision medicines to those in need. Our goal is to have top talent engaged in cutting-edge research, necessitating the identification and cultivation of exceptional partnerships. If you are interested in partnering with us, please fill out our contact form.
Our Current Partners
Professor Nicoletti, affiliated with the University of Catania, is a prominent authority in MIF research, recognized worldwide for expertise in preclinical models related to immunoinflammatory/autoimmune diseases and cancer. Leveraging a robust background in developing in vivo animal models of inflammation, our collaboration with Professor Nicoletti's team will delve into exploring the anti-inflammatory potential of OncoOne’s anti-oxMIF antibodies in arthritis and colitis models.
Professor Tam's research at Imperial College London delves into the role of cytokines in glomerulonephritis, diabetic nephropathy, and renal allograft rejection. Together with his team, he pioneers experimental therapies for glomerulonephritis, employing innovative approaches like soluble cytokine receptors, antagonists, and monoclonal antibodies. Leveraging their expertise, they closely collaborate with OncoOne to exploring the therapeutic efficacy of anti-oxMIF antibodies in experimental glomerulonephritis.
GenScript ProBio, a premier global CDMO, accelerates the drug development journey from discovery to commercialization with its holistic solutions and efficient biologic processes. Their integrated DNA to GMP platform includes cell line development, commercial licensing, and both process and analytical development, leading up to clinical and commercial manufacturing. In November 2021, OncoOne partnered with GenScript ProBio to produce our monoclonal antibodies targeting oxMIF
Adgyl Life Science provides comprehensive services for Discovery, Preclinical, and Early Clinical development programs, ensuring safety assessment and global regulatory compliance. With over 30 years of GLP experience, Adgyl guarantees the highest data quality and reliability. They are our trusted partner for pharmacokinetic and toxicology studies, advancing our therapeutic monoclonal antibodies to clinical trials.
collaborations
Investing in precision medicines
OncoOne is seeking investors for a Series A+ / B financing and is looking for strategic partnerships to propel the development of its pipeline.
We're open to discussing various investment approaches, including the option to fund our platforms/assets separately.
OncoOne welcomes offers from strategic partners for a global licensing transaction, strategic alliance or build-to-buy.
OncoOne generates novel and highly potent antibody modalities targeting oxMIF to treat underserved patient populations living with solid cancers and/or chronic inflammatory diseases.
Collaborating with OncoOne can take many forms:
- Joint Research and Development (R&D)
- Data Sharing and Analysis
- Licensing and Commercialization
Just to name a few.
Be at the forefront of tomorrow: Invest in breakthrough science and innovation with OncoOne.
We are shaping the future:
Pioneering cutting-edge technologies: Join us in revolutionizing industries and tackling global challenges.
High-growth potential: Invest in a company poised for exponential growth and significant returns.
Long-term impact: Be part of something bigger - contribute to positive societal change through groundbreaking advancements.